Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 15/20 | 0.53 |
| ▸ | NQO2 | P16083 | 2/20 | 0.53 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.53 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.53 |
| ▸ | PIP4K2C | Q8TBX8 | 1/20 | 0.53 |
| ▸ | PIM1 | P11309 | 2/20 | 0.40 |
| ▸ | FYN | P06241 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1133778 | 0.87 | MET (0.43) | METNQO2PDE3BPDE3APIP4K2C | |
| SCHEMBL1133760 | 0.86 | MET (0.57) | METNQO2PDE3BPDE3APIP4K2C | |
| SCHEMBL1133692 | 0.85 | MET (0.56) | METNQO2PDE3BPDE3APIP4K2C | |
| SCHEMBL12730563 | 0.85 | MET (0.56) | METNQO2PDE3BPDE3APIP4K2C | |
| SCHEMBL12730491 | 0.85 | MET (0.58) | METNQO2PDE3BPDE3APIP4K2C | |
| SCHEMBL12730567 | 0.84 | MET (0.55) | METNQO2PDE3BPDE3APIP4K2C | |
| SCHEMBL12730626 | 0.84 | MET (0.55) | METNQO2PDE3BPDE3APIP4K2C | |
| SCHEMBL1133664 | 0.83 | MET (0.70) | METNQO2PDE3BPDE3APIP4K2C | |
| SCHEMBL1133805 | 0.83 | MET (0.52) | METNQO2PDE3BPDE3APIP4K2C | |
| SCHEMBL1133875 | 0.82 | MET (0.62) | METNQO2PDE3BPDE3APIP4K2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8497266-B2 | 3-(3-pyrimidin-2-ylbenzyl)-1,2,4-triazolo[4,3-b]pyridazine derivatives as MET kinase inhibitors | MERCK PATENT GMBH (DE) | 2013-07-30 | — | — | US | claimed |
| EP-2285811-B1 | 3-(3-PYRIMIDIN-2-YL-BENZYL)-[1,2,4]-TRIAZOLO[4,3-B]PYRIDAZINE DERIVATIVES AS MET KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2012-12-05 | — | — | EP | claimed |
| US-20110092498-A1 | 3-(3-PYRIMIDIN-2-YLBENZYL)-1,2,4-TRIAZOLO[4,3-B]PYRIDAZINE DERIVATIVES AS MET KINASE INHIBITORS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-04-21 | — | — | US | claimed |
| US-8497266-B2 | 3-(3-pyrimidin-2-ylbenzyl)-1,2,4-triazolo[4,3-b]pyridazine derivatives as MET kinase inhibitors | MERCK PATENT GMBH (DE) | 2013-07-30 | — | — | US | disclosed |
| EP-2285811-B1 | 3-(3-PYRIMIDIN-2-YL-BENZYL)-[1,2,4]-TRIAZOLO[4,3-B]PYRIDAZINE DERIVATIVES AS MET KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2012-12-05 | — | — | EP | disclosed |
| EP-2285811-B1 | 3-(3-PYRIMIDIN-2-YL-BENZYL)-[1,2,4]-TRIAZOLO[4,3-B]PYRIDAZINE DERIVATIVES AS MET KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2012-12-05 | — | — | EP | disclosed |
| US-20110092498-A1 | 3-(3-PYRIMIDIN-2-YLBENZYL)-1,2,4-TRIAZOLO[4,3-B]PYRIDAZINE DERIVATIVES AS MET KINASE INHIBITORS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-04-21 | — | — | US | disclosed |
| US-20110092498-A1 | 3-(3-PYRIMIDIN-2-YLBENZYL)-1,2,4-TRIAZOLO[4,3-B]PYRIDAZINE DERIVATIVES AS MET KINASE INHIBITORS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-04-21 | — | — | US | disclosed |
| US-20110092498-A1 | 3-(3-PYRIMIDIN-2-YLBENZYL)-1,2,4-TRIAZOLO[4,3-B]PYRIDAZINE DERIVATIVES AS MET KINASE INHIBITORS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-04-21 | — | — | US | disclosed |
| EP-2285811-A1 | 3-(3-PYRIMIDIN-2-YL-BENZYL)-Ý1,2,4¨TRIAZOLOÝ4,3-B¨PYRIDAZINE DERIVATIVES AS MET KINASE INHIBITORS | Merck Patent GmbH (DE) | 2011-02-23 | — | — | EP | disclosed |
| WO-2009152920-A1 | 3-(3-PYRIMIDIN-2-YL-BENZYL)-[1,2,4]TRIAZOLO[4,3-B]PYRIDAZINE DERIVATIVES AS MET KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2009-12-23 | — | — | WO | disclosed |
| WO-2009152920-A1 | 3-(3-PYRIMIDIN-2-YL-BENZYL)-[1,2,4]TRIAZOLO[4,3-B]PYRIDAZINE DERIVATIVES AS MET KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2009-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110092498-A1 | 3-(3-PYRIMIDIN-2-YLBENZYL)-1,2,4-TRIAZOLO[4,3-B]PYRIDAZINE DERIVATIVES AS MET KINASE INHIBITORS | RET, ERBB2, MET | MET 3/4885NQO2 1615/4885PDE3B 2032/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.